|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FNBP1L |
Gene summary for FNBP1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FNBP1L | Gene ID | 54874 |
| Gene name | formin binding protein 1 like | |
| Gene Alias | C1orf39 | |
| Cytomap | 1p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q5T0N5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54874 | FNBP1L | CA_HPV_1 | Human | Cervix | CC | 5.67e-05 | -1.46e-01 | 0.0264 |
| 54874 | FNBP1L | CCI_2 | Human | Cervix | CC | 4.98e-03 | 8.25e-01 | 0.5249 |
| 54874 | FNBP1L | CCI_3 | Human | Cervix | CC | 3.87e-07 | 8.26e-01 | 0.516 |
| 54874 | FNBP1L | H2 | Human | Cervix | HSIL_HPV | 4.87e-08 | 4.25e-01 | 0.0632 |
| 54874 | FNBP1L | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.36e-30 | -7.36e-01 | 0.0155 |
| 54874 | FNBP1L | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.08e-11 | -6.56e-01 | -0.1808 |
| 54874 | FNBP1L | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.83e-03 | -7.07e-01 | 0.0216 |
| 54874 | FNBP1L | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.32e-04 | -3.28e-01 | -0.0811 |
| 54874 | FNBP1L | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.47e-11 | -7.79e-01 | -0.1207 |
| 54874 | FNBP1L | HTA11_83_2000001011 | Human | Colorectum | SER | 1.70e-02 | -4.26e-01 | -0.1526 |
| 54874 | FNBP1L | HTA11_696_2000001011 | Human | Colorectum | AD | 2.18e-12 | -4.92e-01 | -0.1464 |
| 54874 | FNBP1L | HTA11_866_2000001011 | Human | Colorectum | AD | 7.08e-06 | -4.25e-01 | -0.1001 |
| 54874 | FNBP1L | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.01e-04 | -7.53e-01 | -0.1706 |
| 54874 | FNBP1L | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.01e-05 | -7.95e-01 | -0.2061 |
| 54874 | FNBP1L | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.40e-05 | -6.58e-01 | -0.1462 |
| 54874 | FNBP1L | HTA11_9341_2000001011 | Human | Colorectum | SER | 4.01e-05 | -9.03e-01 | -0.00410000000000005 |
| 54874 | FNBP1L | HTA11_7862_2000001011 | Human | Colorectum | AD | 4.10e-09 | -7.61e-01 | -0.0179 |
| 54874 | FNBP1L | HTA11_866_3004761011 | Human | Colorectum | AD | 1.14e-19 | -7.20e-01 | 0.096 |
| 54874 | FNBP1L | HTA11_4255_2000001011 | Human | Colorectum | SER | 2.29e-03 | -6.12e-01 | 0.0446 |
| 54874 | FNBP1L | HTA11_9408_2000001011 | Human | Colorectum | AD | 8.31e-04 | -9.27e-01 | 0.0451 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
| GO:000690010 | Cervix | CC | vesicle budding from membrane | 20/2311 | 61/18723 | 2.50e-05 | 4.28e-04 | 20 |
| GO:00068987 | Cervix | CC | receptor-mediated endocytosis | 53/2311 | 244/18723 | 2.52e-05 | 4.29e-04 | 53 |
| GO:00516567 | Cervix | CC | establishment of organelle localization | 76/2311 | 390/18723 | 3.17e-05 | 5.21e-04 | 76 |
| GO:00725836 | Cervix | CC | clathrin-dependent endocytosis | 16/2311 | 47/18723 | 9.56e-05 | 1.25e-03 | 16 |
| GO:00300487 | Cervix | CC | actin filament-based movement | 29/2311 | 127/18723 | 6.91e-04 | 6.33e-03 | 29 |
| GO:00307057 | Cervix | CC | cytoskeleton-dependent intracellular transport | 40/2311 | 195/18723 | 7.92e-04 | 6.99e-03 | 40 |
| GO:01200328 | Cervix | CC | regulation of plasma membrane bounded cell projection assembly | 38/2311 | 186/18723 | 1.14e-03 | 9.35e-03 | 38 |
| GO:00604917 | Cervix | CC | regulation of cell projection assembly | 38/2311 | 188/18723 | 1.40e-03 | 1.10e-02 | 38 |
| GO:00995157 | Cervix | CC | actin filament-based transport | 8/2311 | 21/18723 | 2.44e-03 | 1.71e-02 | 8 |
| GO:00160506 | Cervix | CC | vesicle organization | 54/2311 | 300/18723 | 2.71e-03 | 1.85e-02 | 54 |
| GO:00300507 | Cervix | CC | vesicle transport along actin filament | 7/2311 | 19/18723 | 5.65e-03 | 3.25e-02 | 7 |
| GO:00070092 | Cervix | CC | plasma membrane organization | 28/2311 | 142/18723 | 7.85e-03 | 4.14e-02 | 28 |
| GO:00103243 | Cervix | CC | membrane invagination | 28/2311 | 144/18723 | 9.50e-03 | 4.72e-02 | 28 |
| GO:001032411 | Cervix | HSIL_HPV | membrane invagination | 17/737 | 144/18723 | 5.28e-05 | 1.30e-03 | 17 |
| GO:000689814 | Cervix | HSIL_HPV | receptor-mediated endocytosis | 20/737 | 244/18723 | 1.64e-03 | 1.78e-02 | 20 |
| GO:003004813 | Cervix | HSIL_HPV | actin filament-based movement | 12/737 | 127/18723 | 4.37e-03 | 3.68e-02 | 12 |
| GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
| GO:0006900 | Colorectum | AD | vesicle budding from membrane | 32/3918 | 61/18723 | 5.38e-08 | 2.81e-06 | 32 |
| GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
| hsa05131110 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
| hsa0513125 | Cervix | HSIL_HPV | Shigellosis | 27/459 | 247/8465 | 3.78e-04 | 3.49e-03 | 2.82e-03 | 27 |
| hsa0513135 | Cervix | HSIL_HPV | Shigellosis | 27/459 | 247/8465 | 3.78e-04 | 3.49e-03 | 2.82e-03 | 27 |
| hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa051313 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
| hsa051315 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
| hsa051318 | Colorectum | FAP | Shigellosis | 76/1404 | 247/8465 | 1.57e-08 | 5.84e-07 | 3.55e-07 | 76 |
| hsa051319 | Colorectum | FAP | Shigellosis | 76/1404 | 247/8465 | 1.57e-08 | 5.84e-07 | 3.55e-07 | 76 |
| hsa0513110 | Colorectum | CRC | Shigellosis | 59/1091 | 247/8465 | 1.19e-06 | 5.41e-05 | 3.66e-05 | 59 |
| hsa0513111 | Colorectum | CRC | Shigellosis | 59/1091 | 247/8465 | 1.19e-06 | 5.41e-05 | 3.66e-05 | 59 |
| hsa0513126 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
| hsa05131111 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
| hsa0513127 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
| hsa0513136 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FNBP1L | deletion | Frame_Shift_Del | c.934delN | p.Thr313ProfsTer3 | p.T313Pfs*3 | Q5T0N5 | protein_coding | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |||
| FNBP1L | SNV | Missense_Mutation | novel | c.128N>T | p.Ala43Val | p.A43V | Q5T0N5 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FNBP1L | SNV | Missense_Mutation | novel | c.123N>A | p.Asn41Lys | p.N41K | Q5T0N5 | protein_coding | deleterious(0.01) | probably_damaging(0.98) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FNBP1L | SNV | Missense_Mutation | c.1169N>T | p.Pro390Leu | p.P390L | Q5T0N5 | protein_coding | tolerated(0.06) | benign(0.197) | TCGA-A5-A0GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FNBP1L | SNV | Missense_Mutation | novel | c.1632A>T | p.Lys544Asn | p.K544N | Q5T0N5 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FNBP1L | SNV | Missense_Mutation | c.1279N>A | p.Ala427Thr | p.A427T | Q5T0N5 | protein_coding | deleterious(0) | benign(0.339) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| FNBP1L | SNV | Missense_Mutation | novel | c.194N>T | p.Arg65Leu | p.R65L | Q5T0N5 | protein_coding | deleterious(0.01) | probably_damaging(0.961) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FNBP1L | SNV | Missense_Mutation | novel | c.18N>T | p.Glu6Asp | p.E6D | Q5T0N5 | protein_coding | tolerated(0.22) | benign(0.003) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FNBP1L | SNV | Missense_Mutation | novel | c.1271A>G | p.Gln424Arg | p.Q424R | Q5T0N5 | protein_coding | deleterious(0.04) | probably_damaging(0.98) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| FNBP1L | SNV | Missense_Mutation | c.936N>C | p.Lys312Asn | p.K312N | Q5T0N5 | protein_coding | deleterious(0.01) | possibly_damaging(0.506) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |